Driehaus Capital Management LLC Lowers Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Driehaus Capital Management LLC trimmed its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 18.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,057,410 shares of the company's stock after selling 469,020 shares during the quarter. Driehaus Capital Management LLC owned about 3.59% of Structure Therapeutics worth $55,797,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of GPCR. Geode Capital Management LLC boosted its holdings in Structure Therapeutics by 0.7% during the third quarter. Geode Capital Management LLC now owns 45,225 shares of the company's stock worth $1,985,000 after purchasing an additional 312 shares during the last quarter. Virtus ETF Advisers LLC boosted its stake in Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after purchasing an additional 455 shares during the period. ANTIPODES PARTNERS Ltd lifted its stake in Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after purchasing an additional 553 shares in the last quarter. LPL Financial LLC lifted its stake in Structure Therapeutics by 6.0% in the 4th quarter. LPL Financial LLC now owns 11,485 shares of the company's stock worth $311,000 after purchasing an additional 646 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its holdings in shares of Structure Therapeutics by 12.9% in the 4th quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company's stock worth $201,000 after buying an additional 843 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Stock Down 1.1%

Shares of GPCR traded down $0.26 during trading on Tuesday, reaching $24.36. 263,727 shares of the company traded hands, compared to its average volume of 925,382. Structure Therapeutics Inc. has a twelve month low of $13.22 and a twelve month high of $62.74. The stock has a market cap of $1.40 billion, a PE ratio of -32.92 and a beta of -1.69. The stock has a 50-day simple moving average of $20.98 and a 200-day simple moving average of $26.77.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). On average, equities research analysts predict that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Wall Street Analyst Weigh In

GPCR has been the topic of several recent research reports. Citigroup assumed coverage on shares of Structure Therapeutics in a report on Friday, May 2nd. They set a "buy" rating and a $60.00 target price on the stock. William Blair initiated coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They set an "outperform" rating on the stock. Finally, HC Wainwright dropped their target price on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a report on Monday. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics presently has an average rating of "Buy" and a consensus price target of $78.00.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.